| pubmed-article:20860648 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20860648 | lifeskim:mentions | umls-concept:C1457887 | lld:lifeskim |
| pubmed-article:20860648 | lifeskim:mentions | umls-concept:C0005682 | lld:lifeskim |
| pubmed-article:20860648 | lifeskim:mentions | umls-concept:C0332161 | lld:lifeskim |
| pubmed-article:20860648 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:20860648 | lifeskim:mentions | umls-concept:C2343853 | lld:lifeskim |
| pubmed-article:20860648 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:20860648 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:20860648 | pubmed:dateCreated | 2011-1-31 | lld:pubmed |
| pubmed-article:20860648 | pubmed:abstractText | To assess changes in overactive bladder (OAB) symptoms and patient-reported outcomes in a post hoc analysis in which subjects from a 12-week, open-label, flexible-dose fesoterodine study were stratified according to whether they opted for dose escalation. | lld:pubmed |
| pubmed-article:20860648 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20860648 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20860648 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20860648 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20860648 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20860648 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20860648 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20860648 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:20860648 | pubmed:issn | 1464-410X | lld:pubmed |
| pubmed-article:20860648 | pubmed:author | pubmed-author:TsengLi-JungL... | lld:pubmed |
| pubmed-article:20860648 | pubmed:author | pubmed-author:WyndaeleJean-... | lld:pubmed |
| pubmed-article:20860648 | pubmed:author | pubmed-author:ChooMyung-Soo... | lld:pubmed |
| pubmed-article:20860648 | pubmed:author | pubmed-author:GoldfischerEv... | lld:pubmed |
| pubmed-article:20860648 | pubmed:author | pubmed-author:GongJasonJ | lld:pubmed |
| pubmed-article:20860648 | pubmed:author | pubmed-author:MorrowJon DJD | lld:pubmed |
| pubmed-article:20860648 | pubmed:copyrightInfo | © 2010 PFIZER INC. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL. | lld:pubmed |
| pubmed-article:20860648 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20860648 | pubmed:volume | 107 | lld:pubmed |
| pubmed-article:20860648 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20860648 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20860648 | pubmed:pagination | 603-11 | lld:pubmed |
| pubmed-article:20860648 | pubmed:meshHeading | pubmed-meshheading:20860648... | lld:pubmed |
| pubmed-article:20860648 | pubmed:meshHeading | pubmed-meshheading:20860648... | lld:pubmed |
| pubmed-article:20860648 | pubmed:meshHeading | pubmed-meshheading:20860648... | lld:pubmed |
| pubmed-article:20860648 | pubmed:meshHeading | pubmed-meshheading:20860648... | lld:pubmed |
| pubmed-article:20860648 | pubmed:meshHeading | pubmed-meshheading:20860648... | lld:pubmed |
| pubmed-article:20860648 | pubmed:meshHeading | pubmed-meshheading:20860648... | lld:pubmed |
| pubmed-article:20860648 | pubmed:meshHeading | pubmed-meshheading:20860648... | lld:pubmed |
| pubmed-article:20860648 | pubmed:meshHeading | pubmed-meshheading:20860648... | lld:pubmed |
| pubmed-article:20860648 | pubmed:meshHeading | pubmed-meshheading:20860648... | lld:pubmed |
| pubmed-article:20860648 | pubmed:meshHeading | pubmed-meshheading:20860648... | lld:pubmed |
| pubmed-article:20860648 | pubmed:meshHeading | pubmed-meshheading:20860648... | lld:pubmed |
| pubmed-article:20860648 | pubmed:meshHeading | pubmed-meshheading:20860648... | lld:pubmed |
| pubmed-article:20860648 | pubmed:meshHeading | pubmed-meshheading:20860648... | lld:pubmed |
| pubmed-article:20860648 | pubmed:meshHeading | pubmed-meshheading:20860648... | lld:pubmed |
| pubmed-article:20860648 | pubmed:meshHeading | pubmed-meshheading:20860648... | lld:pubmed |
| pubmed-article:20860648 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20860648 | pubmed:articleTitle | Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study. | lld:pubmed |
| pubmed-article:20860648 | pubmed:affiliation | Department of Urology, Universiteit en Universitair Ziekenhuis Antwerpen, Antwerp, Belgium. wyndaelejj@skynet.be | lld:pubmed |
| pubmed-article:20860648 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20860648 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
